{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T01:25:13Z","timestamp":1769304313564,"version":"3.49.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Sickle cell disease (SCD) is an inherited blood disorder, due to a single point mutation in the \u03b2-globin gene (<jats:italic>HBB<\/jats:italic>) leading to multisystemic manifestations and it affects millions of people worldwide. The monogenic nature of the disease and the availability of autologous hematopoietic stem cells (HSCs) make this disorder an ideal candidate for gene modification strategies. Notably, significant advances in the field of gene therapy and genome editing that took place in the last decade enabled the possibility to develop several strategies for the treatment of SCD. These curative approaches were firstly based on the correction of disease-causing mutations holding the promise for a specific, effective and safe option for patients. Specifically, gene-editing approaches exploiting the homology directed repair pathway were investigated, but soon their limited efficacy in quiescent HSC has curbed their wider development. On the other hand, a number of studies on globin gene regulation, led to the development of several genome editing strategies based on the reactivation of the fetal \u03b3-globin gene (<jats:italic>HBG<\/jats:italic>) by nuclease-mediated targeting of <jats:italic>HBG<\/jats:italic>-repressor elements. Although the efficiency of these strategies seems to be confirmed in preclinical and clinical studies, very little is known about the long-term consequences of these modifications. Moreover, the potential genotoxicity of these nuclease-based strategies must be taken into account, especially when associated with high targeting rates. The recent introduction of nuclease-free genome editing technologies brought along the potential for safer strategies for SCD gene correction, which may also harbor significant advantages over <jats:italic>HBG<\/jats:italic>-reactivating ones. In this Review, we discuss the recent advances in genome editing strategies for the correction of SCD-causing mutations trying to recapitulate the promising strategies currently available and their relative strengths and weaknesses.<\/jats:p>","DOI":"10.3389\/fped.2023.1249275","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T12:55:13Z","timestamp":1698929713000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Genome editing for sickle cell disease: still time to correct?"],"prefix":"10.3389","volume":"11","author":[{"given":"Giulia","family":"Ceglie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Lecis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Canciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Algeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Frati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41573-018-0003-2","article-title":"Therapeutic strategies for sickle cell disease: towards a multi-agent approach","volume":"18","author":"Telen","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979\u20132005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","article-title":"Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia","volume":"7","author":"Walters","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1182\/blood.V128.22.1176.1176","article-title":"Interim results from a phase 1\/2 clinical study of lentiglobin gene therapy for severe sickle cell disease","volume":"128","author":"Kanter","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2018-99-119591","article-title":"Gene therapy for sickle cell Anemia using a modified gamma globin lentivirus vector and reduced intensity conditioning transplant shows promising correction of the disease phenotype","volume":"132","author":"Malik","year":"2018","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood-2018-99-113480","article-title":"Current results of lentiglobin gene therapy in patients with severe sickle cell disease treated under a refined protocol in the phase 1 hgb-206 study","volume":"132","author":"Tisdale","year":"2018","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.exphem.2018.05.004","article-title":"Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice","volume":"64","author":"Sii-Felice","year":"2018","journal-title":"Exp Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1182\/blood.2019000949","article-title":"Lentiviral and genome-editing strategies for the treatment of \u03b2-hemoglobinopathies","volume":"134","author":"Magrin","year":"2019","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv"},{"key":"B11","year":""},{"key":"B12","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.ymthe.2021.03.010","article-title":"A pause in gene therapy: reflecting on the unique challenges of sickle cell disease","volume":"29","author":"Leonard","year":"2021","journal-title":"Mol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature13420","article-title":"Targeted genome editing in human repopulating hematopoietic stem cells","volume":"510","author":"Genovese","year":"2014","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt.3408","article-title":"Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors","volume":"33","author":"Wang","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","article-title":"Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells","volume":"125","author":"Hoban","year":"2015","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 beta-globin gene targeting in human hematopoietic stem cells","volume":"539","author":"Dever","year":"2016","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","article-title":"A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells","volume":"24","author":"Vakulskas","year":"2018","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7955","DOI":"10.1093\/nar\/gkz475","article-title":"Highly efficient editing of the \u03b2-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease","volume":"47","author":"Park","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"432716","DOI":"10.1101\/432716","article-title":"High-level correction of the sickle mutation amplified in vivo during erythroid differentiation","author":"Magis","year":"2019","journal-title":"bioRxiv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1182\/blood-2022-166931","article-title":"Characterization of hemoglobin variants due to in-frame deletions in the \u03b2-globin gene from CRISPR\/Cas9 gene correction for sickle cell disease","volume":"140","author":"Pendergast","year":"2022","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41587-020-0551-y","article-title":"Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking","volume":"38","author":"Ferrari","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"108093","DOI":"10.1016\/j.celrep.2020.108093","article-title":"Controlled cycling and quiescence enables efficient HDR in engraftment-enriched adult hematopoietic stem and progenitor cells","volume":"32","author":"Shin","year":"2020","journal-title":"Cell Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"eabf2444","DOI":"10.1126\/scitranslmed.abf2444","article-title":"Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease","volume":"13","author":"Lattanzi","year":"2021","journal-title":"Sci Transl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/s41467-022-29989-9","article-title":"Targeting double-strand break indel byproducts with secondary guide RNAs improves Cas9 HDR-mediated genome editing efficiencies","volume":"13","author":"Bodai","year":"2022","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1073\/pnas.71.12.4864","article-title":"Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease*","volume":"71","author":"Hofrichter","year":"1974","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/00000441-194804000-00008","article-title":"The significance of the paucity of sickle cells in newborn Negro infants","volume":"215","author":"Watson","year":"1948","journal-title":"Am J Med Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2141.1958.tb03844.x","article-title":"Hereditary persistence of foetal haemoglobin production, and its interaction with the sickle-cell trait","volume":"4","author":"Jacob","year":"1958","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1749-6632.1998.tb10460.x","article-title":"Molecular basis of hereditary persistence of fetal hemoglobin","volume":"850","author":"Forget","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.omtm.2021.09.010","article-title":"CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease","volume":"23","author":"Demirci","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1073\/pnas.1612075113","article-title":"Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: an approach for treating sickle cell disease and \u03b2-thalassemia","volume":"113","author":"Ye","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1182\/blood-2017-10-811505","article-title":"Induction of fetal hemoglobin synthesis by CRISPR\/Cas9-mediated editing of the human \u03b2-globin locus","volume":"131","author":"Antoniani","year":"2018","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/jcm10030482","article-title":"Genome editing for \u03b2-hemoglobinopathies: advances and challenges","volume":"10","author":"Frati","year":"2021","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41588-018-0085-0","article-title":"Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding","volume":"50","author":"Martyn","year":"2018","journal-title":"Nat Genet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm.4170","article-title":"A genome-editing strategy to treat \u03b2-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition","volume":"22","author":"Traxler","year":"2016","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1182\/bloodadvances.2019000820","article-title":"Genome editing of HBG1 and HBG2 to induce fetal hemoglobin","volume":"3","author":"M\u00e9tais","year":"2019","journal-title":"Blood Adv"},{"key":"B37","doi-asserted-by":"publisher","first-page":"eaaw3768","DOI":"10.1126\/scitranslmed.aaw3768","article-title":"Therapeutically relevant engraftment of a CRISPR-Cas9\u2013edited HSC-enriched population with HbF reactivation in nonhuman primates","volume":"11","author":"Humbert","year":"2019","journal-title":"Sci Transl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"eaay9392","DOI":"10.1126\/sciadv.aay9392","article-title":"Editing a \u03b3-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype","volume":"6","author":"Weber","year":"2000","journal-title":"Sci Adv"},{"key":"B39","doi-asserted-by":"publisher","first-page":"107993","DOI":"10.1016\/j.celrep.2020.107993","article-title":"ATF4 regulates MYB to increase \u03b3-globin in response to loss of \u03b2-globin","volume":"32","author":"Boontanrart","year":"2020","journal-title":"Cell Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.biocel.2007.01.020","article-title":"Activating transcription factor 4","volume":"40","author":"Ameri","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.smim.2008.05.003","article-title":"Critical roles for c-myb in hematopoietic progenitor cells","volume":"20","author":"Greig","year":"2008","journal-title":"Semin Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level","volume":"342","author":"Bauer","year":"2013","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A Enhancer dissection by Cas9-mediated in situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.omtm.2016.12.009","article-title":"Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34+ hematopoietic stem and progenitor cells","volume":"4","author":"Chang","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B45","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6677","DOI":"10.1172\/JCI140189","article-title":"BCL11A enhancer\u2013edited hematopoietic stem cells persist in rhesus monkeys without toxicity","volume":"130","author":"Demirci","year":"2020","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/blood.2020010020","article-title":"Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo","volume":"138","author":"Psatha","year":"2021","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"174788","DOI":"10.1016\/j.ejphar.2022.174788","article-title":"CRISPR\/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression","volume":"918","author":"Han","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.omtm.2021.10.008","article-title":"Multiplex CRISPR\/Cas9 genome editing in hematopoietic stem cells for fetal hemoglobin reinduction generates chromosomal translocations","volume":"23","author":"Samuelson","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR\u2013Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat Methods"},{"key":"B51","doi-asserted-by":"publisher","first-page":"04.05.438458","DOI":"10.1101\/2021.04.05.438458","article-title":"Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects","author":"Petri","year":"2021","journal-title":"bioRxiv"},{"key":"B52","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41587-020-0646-5","article-title":"Massively parallel kinetic profiling of natural and engineered CRISPR nucleases","volume":"39","author":"Jones","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.aav9023","article-title":"Unbiased detection of CRISPR off-targets in vivo using DISCOVER-seq","volume":"364","author":"Wienert","year":"2019","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","article-title":"Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-seq","volume":"28","author":"Turchiano","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/crispr.2021.0120","article-title":"ON-target adverse events of CRISPR-Cas9 nuclease: more chaotic than expected","volume":"5","author":"Boutin","year":"2022","journal-title":"CRISPR J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.1038\/s41586-018-0380-z","article-title":"Large deletions induced by Cas9 cleavage","volume":"560","author":"Adikusuma","year":"2018","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","article-title":"CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations","volume":"10","author":"Cullot","year":"2019","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR\u2013Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat Genet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41587-022-01377-0","article-title":"Frequent aneuploidy in primary human T cells after CRISPR\u2013Cas9 cleavage","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1038\/s41467-021-25190-6","article-title":"CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells","volume":"12","author":"Boutin","year":"2021","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ymthe.2017.11.001","article-title":"Characterization of gene alterations following editing of the \u03b2-globin gene locus in hematopoietic stem\/progenitor cells","volume":"26","author":"Long","year":"2018","journal-title":"Mol Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/mt.2016.148","article-title":"CRISPR\/Cas9-mediated correction of the sickle mutation in human CD34+ cells","volume":"24","author":"Hoban","year":"2016","journal-title":"Mol Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/nbt.4198","article-title":"Efficient base editing in methylated regions with a human APOBEC3A-Cas9 fusion","volume":"36","author":"Wang","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"618406","DOI":"10.3389\/fgeed.2021.618406","article-title":"Base and prime editing technologies for blood disorders","volume":"3","author":"Antoniou","year":"2021","journal-title":"Front Genome Ed"},{"key":"B70","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1182\/blood-2021-150922","article-title":"Conversion of HbS to hb G-makassar by adenine base editing is compatible with normal hemoglobin function","volume":"138","author":"Chu","year":"2021","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","article-title":"Directed evolution of adenine base editors with increased activity and therapeutic application","volume":"38","author":"Gaudelli","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1038\/s41467-022-34493-1","article-title":"Base-editing-mediated dissection of a \u03b3-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression","volume":"13","author":"Antoniou","year":"2022","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41422-019-0267-z","article-title":"Reactivation of \u03b3-globin expression through Cas9 or base editor to treat \u03b2-hemoglobinopathies","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","article-title":"Therapeutic base editing of human hematopoietic stem cells","volume":"26","author":"Zeng","year":"2020","journal-title":"Nat Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","article-title":"Engineered pegRNAs improve prime editing efficiency","volume":"40","author":"Nelson","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41551-023-01026-0","article-title":"Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice","volume":"7","author":"Everette","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2018-03-838540","article-title":"Reactivation of \u03b3-globin in adult \u03b2-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1182\/blood.2022018252","article-title":"In vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/hum.2021.013","article-title":"CRISPR\/Cas-dependent and nuclease-free in vivo therapeutic gene editing","volume":"32","author":"Dasgupta","year":"2021","journal-title":"Hum Gene Ther"},{"key":"B83","doi-asserted-by":"publisher","first-page":"103060","DOI":"10.1016\/j.transci.2021.103060","article-title":"CRISPR\/Cas9 gene editing for curing sickle cell disease","volume":"60","author":"Park","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"B84","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"key":"B85","author":"Locatelli","year":""},{"key":"B86","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12887-020-02187-6","article-title":"High fetal hemoglobin level is associated with increased risk of cerebral vasculopathy in children with sickle cell disease in Mayotte","volume":"20","author":"Chamouine","year":"2020","journal-title":"BMC Pediatr"},{"key":"B88","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood-2013-09-528067","article-title":"Fetal hemoglobin in sickle cell anemia: a glass half full?","volume":"123","author":"Steinberg","year":"2014","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/j.ymthe.2023.03.007","article-title":"An optimized SpCas9 high-fidelity variant for direct protein delivery","volume":"31","author":"Pedrazzoli","year":"2023","journal-title":"Mol Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bjh.15902","article-title":"Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery","volume":"186","author":"Leonard","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1249275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T12:55:16Z","timestamp":1698929716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1249275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":90,"alternative-id":["10.3389\/fped.2023.1249275"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1249275","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"article-number":"1249275"}}